(Total Views: 376)
Posted On: 02/11/2022 7:36:24 AM
Post# of 92
CAN INTERCEPT MAKE IT TO THE FINISHING LINE IN NASH?
$ICPT
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a biopharmaceutical Company aiming to create novel therapeutics for the treatment of progressive non-viral liver diseases. The Company has upcoming catalysts in the form of the topline data from a crucial Phase 3 REVERSE trial, a active late-stage Phase 3 study that is evaluating compensated cirrhosis due to NASH.
Read on to find out more!
https://www.aviseanalytics.com/can-intercept-...e-in-nash/
$ICPT
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a biopharmaceutical Company aiming to create novel therapeutics for the treatment of progressive non-viral liver diseases. The Company has upcoming catalysts in the form of the topline data from a crucial Phase 3 REVERSE trial, a active late-stage Phase 3 study that is evaluating compensated cirrhosis due to NASH.
Read on to find out more!
https://www.aviseanalytics.com/can-intercept-...e-in-nash/
(0)
(0)Scroll down for more posts ▼
